Table 2.
Ongoing clinical trials using cytomegalovirus-specific cellular immunotherapy for allo-SCT patients including haploidentical SCT (accessed on 5 Oct 2021, ClinicalTrials.gov).
| Intervention | Patients | Enrollment | Phase | Duration | NCT number | Status |
|---|---|---|---|---|---|---|
| Donor-derived viral specific T-cells (VSTs) | Stem cell transplant recipients who have evidence of viral infection or reactivation | 450 | Phase 1/Phase 2 | 2014-2024 | NCT02048332 | Recruiting |
| HLA-matched VSTs | EBV, CMV, adenovirus, and BK infections post allogeneic SCT | 47 | Phase 1 | 2021-2024 | NCT04013802 | Recruiting |
| Multivirus (CMV, EBV, AdV)-specific T cells | Chemo-refractory viral infections after allo-HSCT | 149 | Phase 3 | 2019-2022 | NCT04832607 | Recruiting |
| Third party donor derived CMVpp65 specific T-cells | CMV Infection or persistent CMV viremia after allogeneic hematopoietic stem cell transplantation | 41 | Phase 2 | 2014-2022 | NCT02136797 | Recruiting |
| Adaptive NK cells infusion post transplantation | CMV infection in patients post haploidentical transplantation | 30 | Not Applicable | 2020-2021 | NCT04320303 | Recruiting |
| CMV-specific T cells | Relapsing or therapy refractory CMV infection after allogeneic stem cell transplantation | 20 | Phase 2 | 2016-2022 | NCT03067155 | Recruiting |
| CMV cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System | Refractory cytomegalovirus (CMV) infection post allogeneic hematopoietic stem cell transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant | 20 | Phase 2 | 2018-2023 | NCT03266640 | Recruiting |
| Direct infusions of donor-derived virus-specific T-cells using the Cytokine Capture System | Recipients of hematopoietic stem cell transplantation with post-transplant viral infections | 12 | Phase 2 | 2014-2022 | NCT02007356 | Recruiting |
| Emergency access to CMV pp65/IE-1 specific cytotoxic T lymphocytes | Recipients of allogeneic stem cell transplants with persistent or therapy refractory Infections | 20 | Phase 1 | 2008-2014 | NCT00769613 | Active, not recruiting |
| Viral specific T-Lymphocytes by Cytokine Capture System (CCS) | Infection with adenovirus, cytomegalovirus or Epstein-Barr Virus after hematopoietic cell transplantation or solid organ transplantation and in patients with compromised immunity | 25 | Phase 1/Phase 2 | 2021-2028 | NCT04364178 | Recruiting |
| CMV specific adoptive t-cells | Opportunistic cytomegalovirus infection occurring after stem cell transplant | 20 | Early Phase 1 | 2016-2022 | NCT02982902 | Recruiting |
| Virus specific T-cell (VST) infusion | Enhancing T-cell reconstitution before or after hematopoietic stem cell transplantation | 60 | Phase 1/Phase 2 | 2018-2023 | NCT03475212 | Active, not recruiting |
| CMV-specific T-cells | CMV in pediatric and adult immunocompromised patients or recipients of allogeneic stem cell transplantation | 20 | Phase 1 | 2020-2026 | NCT03798301 | Recruiting |
| Allogeneic cytomegalovirus-specific cytotoxic T lymphocytes | CMV reactivation or infection in participants who have undergone stem cell transplant or solid organ transplant | 10 | Early Phase 1 | 2020-2021 | NCT03665675 | Recruiting |
| Adoptive cell immunotherapy | Prophylaxis of cytomegalovirus infection in haploidentical transplantation of hematopoietic progenitors | 15 | Phase 2 | 2021-2022 | NCT04056533 | Not yet recruiting |
| Adoptive transfer of selected cytomegalovirus-specific cytotoxic T lymphocytes (CMV-CTL) | Patients at risk of CMV Disease after allogeneic stem cell transplantation (SCT) | 78 | Phase 2 | 2009-2013 | NCT00986557 | Recruiting |
| Donor derived cytomegalovirus specific T lymphocytes | Treatment of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation | 30 | Phase 4 | 2016-2021 | NCT03004261 | Recruiting |